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neuropathy, distal sensory loss, and cerebellar eye move-
ment disturbances. We screened 96 index subjects from 
recessive HSP families for mutation and identiﬁed one 
family with two sibs carrying mutations in DDHD1 gene. 
were performed, including MR spectroscopy of brain and 
muscle of the two mutated patients. Two novel heterozy-
gous mutations in DDHD1 were found in the affected 
the SPG28 subtype. Of note, MR spectroscopy of brain and 
Abstract Mutations in DDHD1 gene have been associ- muscle in these patients indicated a mild deﬁcit of brain 
ated with the SPG28 subtype of Hereditary Spastic Para- energy metabolism in the oldest and most severely affected 
paresis (HSP). Clinical phenotype includes axonal patient, while an impairment of energy metabolism was 
found in the skeletal muscle of both patients. Unlike the 
DDHD2 mutated patients, no evidence of lipid accumula-
tion in the brain was found. Our data along with those 
previously reported suggest a dysfunction in the OXPHOS 
Clinical, neuropsychological, and neuroimaging studies system possibly due to mitochondrial lipid content modi- 
ﬁcation, which could be a central mechanism in the path-
ogenesis of SPG28. 
members of one family, with clinical features overlapping Keywords Hereditary spastic paraplegia _ SPG28 _ 
Proton magnetic resonance spectroscopy _ Phosphorus 
magnetic resonance spectroscopy 
Introduction 
Hereditary spastic paraplegia (HSP) is a clinical and 
genetic heterogeneous group of disorders sharing the 
common feature of progressive spasticity in the lower 
extremities. Pure forms are characterized by isolated spinal 
involvement, while complicated ones show the presence of 
other neurologic or systemic abnormalities [1]. Among the 
71 different subtypes of HSP so far identiﬁed [1, 2], a 
subset of them is associated with defects in genes involved 
in different aspects of lipid metabolism, such as SPG54, 
SPG28, SPG56, SPG46, SPG26, and SPG5 [1]. SPG28 was 
ﬁrst associated with a pure form of HSP [3], then mutations 
in the causative gene DDHD1 were found in additional 
three families [4] presenting with a clinical phenotype, 
including axonal neuropathy, distal sensory loss, and cer-
ebellar eye movement disturbances [3, 4]. DDHD1 encodes 
a cytosolic phosphatidic acid-preferring phospholipase A1 
(PA-PLA1). Mutations in DDHD1 were demonstrated to 
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increased oxidative stress in patients’ lymphoblasts [4]. In 
a screening for mutations in DDHD1 carried out in 96 
index patients from HSP families, we identiﬁed one family 
carrying two novel mutations in this gene. Here we report 
the detailed clinical and neuropsychological characteriza-
tion of this family. We also investigated the presence of 
lipid accumulation and checked the energy metabolism in 
this form of HSP by brain and muscle magnetic resonance 
Patients and methods 
A series of 96 index patients from families with AR-HSP 
Criteria [5]. Detailed methods are provided in online elec-
tronic supplementary ﬁles. Screening for DDHD1 (SPG28) 
mutations led to the identiﬁcation of one single family 
carrying mutations in DDHD1, clinically described below. 
Genetic analysis 
We obtained blood samples and clinical data from affected 
informed consent approved by the Ethics Committee of the 
E. Medea Scientiﬁc Institute. Mutation analysis was per-
formed by targeted resequencing of the coding exons of 
DDHD1 gene, using an amplicon-based high-throughput 
Technical details are available in online electronic sup-
plementary ﬁles. Sanger sequencing was also used to val-
idate all variants identiﬁed. 
Results 
Mutation analysis 
Mutation screening of DDHD1 coding exons in 96 index 
HSP patients led to the identiﬁcation of two compound 
heterozygous mutations in DDHD1 in the two affected sibs 
of a single family (Fig. 1). A single nucleotide insertion in 
exon 6 (c.1422_1423insA, p.Val476Serfs*20) and a single 
nucleotide deletion in exon 11 (c.2279delT- p.Met760-
Serfs*37) were detected, both leading to early protein 
truncation either upstream or within the DDHD domain, 
respectively. Thus, the truncated DDHD1 protein deriving 
from any of the two alleles is lacking an integral DDHD 
domain, which is responsible for the phospholipase activity 
of DDHD1 protein, thereby leading to a likely loss of 
protein function. 
induce alterations of mitochondrial bioenergetics with Clinical data of the family carrying the DDHD1 
mutation 
The family we describe includes two affected subjects (pt 
II-2 and II-3) of three siblings. The parents were unaffected 
and not consanguineous. Patient II-2 (index) complained 
progressive gait disturbances since age 15 years due to leg 
weakness and ‘‘stiffness’’ while walking, and unsteadiness. 
After 20 years from symptoms onset, he was still able to 
spectroscopy (MRS). walk unassisted. Neurologic examination showed mild 
distal muscle weakness in legs, bilateral lower limb spas-
ticity with brisk tendon reﬂexes and Babinski sign. Claw 
foot and lumbar scoliosis were present. Gait was spastic. 
Patient II-3 had slowly progressing walking difﬁculties 
from age of 16 years. Neurologic examination revealed 
were clinically evaluated and genetically screened for       tongue fasciculations associated with slight wasting and 
DDHD1 mutations. Diagnosis was based on Harding’s       weakness, increased muscle tone, hyperreﬂexia in the 
lower limbs with bilateral Babinski sign and spastic gait. 
Neurophysiological studies were performed. Concentric 
needle EMG in upper and lower limb muscles disclosed 
chronic neurogenic changes in both patients. Electroneu-
rographic studies of the tibial nerves showed slight slowing 
of motor conduction velocity (23 %) and marked reduction 
of compound motor action potential (93 %) in patient II-2; 
normal ﬁndings were detected in patient II-3. Transcranial 
and unaffected subjects of the pedigree under a protocol of magnetic stimulation showed abnormal conduction in 
corticospinal pathways (Table 1). Visual evoked potentials 
were normal. Sensory evoked potentials (SEPs) were nor-
mal in patient II-3, whereas in patient II-2 SEPs to stim-
ulation of posterior tibial nerves at the ankle showed no 
pooled-sequencing method for amplicon generation. peripheral responses, absent spinal responses at D10 and 
increased P40 latency (?12 %) with decreased amplitude 
of 0.4 lV (normal value 2 ± 0.5; mean ± 2SD). 
Neuropsychological studies 
Mini mental state evaluation and brief mental deterioration 
battery scores were normal. However, neuropsychological 
examination showed deﬁcits in simple analogy tests in both 
patients and also in phonemic and semantic verbal ﬂuency 
in patient II-2 (Table 1). 
Magnetic resonance imaging and magnetic resonance 
spectroscopy investigations 
Structural brain MRI in both patients did not show any 
morphology or signal intensity changes. Also, the mor-
phometric and volumetric analysis of cortical and subcor-
tical regions was normal. 
Brain 
1
H-MRS in the cerebrospinal ﬂuid of the lateral 
ventricles detected a mild pathological accumulation of 
lactate in patient II-2 (Fig. 1), whereas no lactate was 
found in patient II-3. 
Brain cortical 
1
H-MRS evaluation showed normal con- 
(membrane turnover/density marker), and of myo-inositol 
(osmolite and glial marker) in both patients. No patho-
logical accumulation of macromolecules at 0.9 or 1.3 ppm 
was detected. 
Compared to healthy controls, 
31
P-MRS of muscle at 
tent of N-acetyl-aspartate (neuronal marker), choline rest showed a reduction of the phosphocreatine/inorganic 
phosphate (PCr/Pi) ratio both in patient II-2 (=3.90 vs. 
7.29 ± 0.89, mean ± standard deviation, in healthy sub-
jects) (Fig. 1) and in patient II-3 (=2.80). Muscle pH was 
normal. 
Fig. 1 a The pedigrees of the family carrying the DDHD1 mutations. 
Diamond symbols are for anonymity reasons; black and white symbols 
indicate affected and healthy subjects, respectively; the arrow 
indicates the proband. Electropherograms of the mutations identiﬁed 
in the study. The inserted/deleted nucleotides are boxed. The parents 
are carriers of the mutations (the exon 6 mutation inherited from the 
mother, the exon 11 mutation inherited from the father). Schematic 
representation of DDHD1 protein with the DDHD domain in the 
COOH-terminus. In the upper part: the mutations identiﬁed in this 
study; the known mutations are indicated below. b 1H-MRS spectrum 
obtained from the CSF of the lateral ventriculi of patient II-2 showing 
a pathological mild accumulation of lactate (Lac) (rectangle). c 
31
P-
MRS spectrum obtained at rest from the left calf muscle of patient II-
2 showing an increase of Pi peak (arrow). Pi inorganic phosphate, 
PCr phosphocreatine, ATP adenosine-triphosphate 
Discussion 
We describe the clinical, neuroradiological, and neuro-
psychological features of two affected sibs of an HSP 
family carrying compound heterozygous frameshift muta-
tions in the DDHD1 gene leading to the loss of the DDHD 
domain. DDHD1 is a phosphatidic acid-preferring phos-
pholipase A1 and this activity is strictly related to the 
DDHD domain integrity. Therefore, the mutations here 
identiﬁed should lead to loss of protein function. This 
family was identiﬁed in a mutation screening of DDHD1 
carried out in 96 index patients from autosomal recessive 
HSP families, thus indicating that SPG28 could not be a 
frequent subtype of either pure or mildly complicated HSP 
(cHSP). 
The clinical history of the DDHD1 mutated patients 
described here overlaps the one of the previously reported 
SPG28-related families [3, 4]. It is characterized by an 
apparently pure phenotype with evidence of pyramidal 
tract involvement in the second decade of life (median age 
15 years) and progressive loss of walking independence. 
Neurophysiological investigations revealed signs of corti-
cospinal tracts involvement. Neuropsychological testing 
disclosed subtle deﬁcits in verbal abstract thinking and 
verbal ﬂuency suggestive of frontal lobe dysfunction [6, 7]. 
These ﬁndings suggest that, also in an apparently pure 
phenotype, a more widespread pathological involvement 
could be demonstrated and is concordant with previous 
studies showing an involvement of the frontal lobe in cHSP 
[8]. 
We also assessed the energy metabolism through brain 
1
H- and muscle 
31
P- MRS, also looking for the presence of 
brain accumulation of lipids on the basis of a previous 
report of an abnormal lipid peak in the brain of patients 
carrying truncating mutations in the DDHD domain of 
DDHD2 [4] DDHD2 together with DDHD1 and SEC23IP 
are members of the mammalian family of intracellular 
phospholipase A1, sharing a lipase motif (GxSxG) and the 
DDHD domain [9]. 
While structural brain MRI in our DDHD1 mutated 
patients was normal, a mild deﬁcit of brain energy 
metabolism in the oldest and most severely affected patient 
II-2 was found, as shown by a pathological accumulation of 
ventricular lactate. The pathological presence of lactic acid 
in the cerebrospinal ﬂuid is typically observed in patients 
with primary mitochondrial diseases [10] and it is sec-
ondary to oxidative phosphorylation impairment. In skel-
etal muscle at rest, in both patients, 
31
P-MRS showed a 
signiﬁcant reduction of PCr to Pi ratio. Skeletal muscle 
PCr/Pi ratio indicates a reduction of cellular energy reserve 
(i.e., phosphorylation potential) and is a typical ﬁnding in 
patients with primary mitochondrial myopathies. In con-
trast with patients carrying mutations in the DDHD2 gene, T
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 in none of the DDHD1 patients brain lipid accumulation 
was detected using 
1
H-MRS. 
Although belonging to the same protein family with 
similar hydrolyzing activity (an acyl group of phospholipids 
at the sn-1 position) and similarly implicated in organelle 
biogenesis and membrane trafﬁcking, DDHD1 and DDHD2 
show different subcellular localization. DDHD2 is more 
stably associated with the Golgi/endoplasmic reticulum 
[11] while DDHD1 is mainly localized in cytosol with a 
partial localization in microsomes and mitochondria [12]. In 
addition, DDHD1 has been recently involved in the for-
mation of lysophosphatidylinositol (LPI), and in particular 
of 2-arachidonoyl LPI [12], a lipid mediator with various 
physiological functions, including Ca
2? 
mobilization and 
cell migration and proliferation [13]. 
This partly explains such different functional conse-
quences deriving from mutations in the DDHD domain of 
the two proteins, including the different clinical phenotypes 
(severe and complicated in DDHD2/SPG54 vs. pure or 
mildly complicated in DDHD1/SPG28 subtype). 
The ﬁndings here reported, the partial localization of 
DDHD1 at mitochondrial level, along with the previous 
demonstration of a reduction of mean mitochondrial res-
piration activities and ATP levels, together with an incre-
ment of cytosolic hydrogen peroxide in SPG28 
lymphoblasts compared to controls [4] overall suggest a 
dysfunction in the OXPHOS system, possibly due to 
mitochondrial lipid content modiﬁcation. Mitochondrial 
phospholipids, including phosphatidic acid, are involved in 
different processes such as mitochondrial membrane 
integrity and morphology maintenance, fusion and ﬁssion, 
protein import, and apoptosis [14]. Mitochondrial dynam-
ics, through fusion and ﬁssion, is fundamental for mito-
chondrial function and may be affected by alteration of 
lipid content [15]. 
The mitochondrial dysfunctions occurring in both brain 
and skeletal muscle of DDHD1 patients here reported 
could likely represent a central mechanism in the patho-
genesis of SPG28. 
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